The ERK and JNK pathways in the regulation of metabolic reprogramming

Salvatore Papa1 · Pui Man Choy1,2 · Concetta Bubici3,4

Received: 30 April 2018 / Revised: 24 September 2018 / Accepted: 23 October 2018
© The Author(s) 2018. This article is published with open access

Abstract
Most tumor cells reprogram their glucose metabolism as a result of mutations in oncogenes and tumor suppressors, leading to the constitutive activation of signaling pathways involved in cell growth. This metabolic reprogramming, known as aerobic glycolysis or the Warburg effect, allows tumor cells to sustain their fast proliferation and evade apoptosis. Interfering with oncogenic signaling pathways that regulate the Warburg effect in cancer cells has therefore become an attractive anticancer strategy. However, evidence for the occurrence of the Warburg effect in physiological processes has also been documented. As such, close consideration of which signaling pathways are beneficial targets and the effect of their inhibition on physiological processes are essential. The MAPK/ERK and MAPK/JNK pathways, crucial for normal cellular responses to extracellular stimuli, have recently emerged as key regulators of the Warburg effect during tumorigenesis and normal cellular functions. In this review, we summarize our current understanding of the roles of the ERK and JNK pathways in controlling the Warburg effect in cancer and discuss their implication in controlling this metabolic reprogramming in physiological processes and opportunities for targeting their downstream effectors for therapeutic purposes.

Introduction
Cellular metabolism is the process by which a living cell converts nutrients into energy or new macromolecules through a series of biochemical reactions, known as catabolic pathways and anabolic pathways, respectively [1]. Through catabolic pathways, carbon fuels such as glucose, fatty acids, and glutamine are broken down to generate energy in the form of adenosine triphosphate (ATP), which is used to maintain cellular functions and construct new cellular components [1, 2]. There are two major ATP-producing pathways in mammalian cells, glycolysis and oxidative phosphorylation (OXPHOS) [3]. These two metabolic pathways function in concert to provide energy for cellular and tissue homeostasis. During glycolysis, a normal differentiated cell oxidizes glucose into pyruvate, which enters the mitochondria to be further oxidized to carbon dioxide in the tricarboxylic acid (TCA) cycle, producing the reduced electron carriers nicotinimide adenine dinucleotide (NADH) and flavin adenine dinucleotide (FADH2). NADH and FADH2 are then used during OXPHOS to generate 36 molecules of ATP per molecule of glucose. OXPHOS is the main ATP-producing pathway in normal cells and is strictly dependent on the presence of oxygen [3]. In fact, in the absence of oxygen, the pyruvate produced by glycolysis is converted to lactate with a net production of two molecules of NADH and only two molecules of ATP. Such a low ATP-producing pathway is referred to as anaerobic glycolysis or glucose fermentation and takes place in the cytoplasm. Thus, to survive in low oxygen conditions, a normal differentiated cell re-adjusts its glucose metabolism by shifting toward anaerobic glycolysis. Unexpectedly, rapidly proliferating tumor cells adopt...
this inefficient ATP-producing pathway as their chief manner of energy harvest even in the presence of sufficient levels of oxygen [4–6]. This is not a new concept as it was anticipated by Otto Warburg more than 90 years ago when he observed that tumor slices and ascites cancer cells display an enhanced rate of glycolysis and produce larger amount of lactate compared to their normal counterparts despite the presence of adequate levels of oxygen for mitochondrial respiration [7]. Subsequent works have revealed that this metabolic phenomenon is not restricted to cancer cells, but it is a common metabolic feature among all mammalian cells during periods of rapid proliferation [8–10].

Over the past decade, aerobic glycolysis has taken center stage in cancer research, because it is characteristic of essentially all types of cancer as well as its implications for cancer diagnosis and monitoring [4–6, 11–14]. It is now appreciated that aerobic glycolysis in cancer occurs downstream of molecular signaling pathways, often driven by mutations in oncogenes or tumor suppressors [15–18]. Evidence have pointed out that signaling pathways involving oncogenes and tumor suppressors play a direct role in promoting the conversion of energy metabolism to aerobic glycolysis in addition to their well-known functions in inducing aberrant cell proliferation or attenuating apoptosis [19–22]. Among the many signaling pathways that respond to oncogenic mutational events and regulate proliferation and apoptosis as well as aerobic glycolysis are members of the mitogen-activated protein kinases (MAPKs) family. There are three well-characterized subfamilies of MAPKs in mammals: the extracellular signal-regulated kinases (ERKs), the c-Jun N-terminal kinases (JNKs), and the p38 kinases [23]. Activation of each MAPK signaling follows a three-tier kinase module in which a MAP3K phosphorylates and activates a MAP2K, which in turn phosphorylates and activates a MAPK. Once activated, the MAPKs control a diversity of cellular responses, such as proliferation, differentiation, cell death, and survival [23, 24].

Of the three types of MAPKs, ERKs and JNKs have been recently shown to regulate the redirecting of energy harvest to glycolysis in both malignant and highly proliferative cells by affecting the activity of key metabolic regulators. Here we provide a comprehensive overview of the functional implications and our current knowledge of the role of ERK and JNK signaling pathways in regulating glucose metabolism of highly proliferating cells in cancer and some physiological contexts, such as inflammation and immunity as well as tissue development.

The glycolytic pathway and its regulation

Most mammalian cells use glucose as the primary carbon sources for the production of ATP and synthesis of cellular components, such as proteins, lipids, and nucleic acids [25–27]. They normally take up glucose from extracellular fluid into the cell only when stimulated by extracellular growth factors to growth and divide [28–31]. For example, the binding of growth factors to receptor tyrosine kinases (RTKs) activates the phosphatidylinositol 3-kinase (PI3K)/Akt pathway to stimulate cellular glucose uptake and glycolysis along with cell growth and survival [19, 32] by enhancing both the transcriptional expression and translocation to the cell surface of glucose transporters (GLUTs) [15, 16, 33]. Once in the cell, glucose is phosphorylated by the first enzyme of the glycolytic pathway hexokinase (HK) to form glucose-6-phosphate (G6P), which in turn serves as an allosteric inhibitor of HK (Fig. 1). HK is stimulated following activation of Akt, so that PI3K/Akt signaling not only facilitates the increase in glucose uptake but also enables glucose progression through the glycolytic pathway [17, 18, 31, 34]. G6P has then three possible metabolic fates within the cell. It can be converted into fructose-6-phosphate (F6P) in the glycolytic pathway or can be oxidized by the pentose phosphate pathway (PPP) or enter the synthesis pathway of glycogen, a storage form of glucose (reviewed in ref. [35]) (Fig. 1). If a cell is instructed to continue glycolysis, F6P is further phosphorylated by the enzyme phosphofructokinase 1 (PFK1) to form fructose 1,6-biphosphate (F1,6BP), which then is cleaved into two triose phosphates, glyceraldehyde 3-phosphate (GAP) and dihydroxyacetone phosphate (DHAP) (Fig. 1) [2, 3]. Unlike GAP, which is the substrate for the next reaction in glycolysis, DHAP does not undergo direct glycolysis. It can either be used to generate glyceraldehyde-3-phosphate (G3P), an important precursor for the synthesis of structural lipids of cell membranes, or can proceed further along the glycolytic pathway via its conversion to GAP by triose phosphate isomerase. As a result, oxidation of one molecule of glucose forms two molecules of GAP, both of which are converted into pyruvate in a sequence of five reactions that generates ATP and NADH (Fig. 1) [2, 3]. The final reaction in this sequence is the conversion of phosphoenolpyruvate (PEP) to pyruvate, which can then enter into TCA cycle by its conversion to acetyl-coenzyme A (acetyl-CoA) or be converted into lactate depending on cell type and availability of oxygen [2, 3]. The conversion of PEP to pyruvate is catalyzed by pyruvate kinase (PK), a homotetrameric enzyme that exists in mammals as four isoforms (PKL, PKR, PKM1, and PKM2) with different expression patterns and regulatory mechanisms [36–42]. Unlike PKM1, which is constitutively active and insensitive to allosteric effectors, the PKM2, PKL, and PKR isoforms are subject to allosteric regulation that affects enzyme activity by the direct binding of effectors. For example, the glycolytic intermediate F1,6BP stimulates PKM2 by increasing its affinity for PEP (the catalytic substrate of PK), promoting tetramerization,
and stabilizing the tetrameric active conformation of PKM2. Conversely, PKM2 is inhibited by the binding to tyrosine phosphorylated peptides, which induce the release of F1,6BP resulting in the stabilization of the inactive dimeric conformation of PKM2, an event associated with low PK activity [36]. Besides being allosterically regulated by diverse metabolites, PKM2 is also negatively regulated by covalent modifications, including phosphorylation, acetylation, and oxidation. It is now appreciated that low PKM2 activity in cells allows the accumulation of glycolytic

Fig. 1 Schematic diagram of glycolysis. Schematic drawing shows the steps and specific enzymes of the glycolytic pathway that converts glucose in pyruvate through a series of enzymatic reactions catalyzed by hexokinase (HK), phosphoglucone isomerase (PGI), phosphofructokinase (PFK), aldolase (ALDOA), glyceraldehyde 3 phosphate dehydrogenase (GAPDH), phosphoglycerate kinase (PGK), phosphoglycerate mutase (PGM), enolase (ENO), and pyruvate kinase (PK). Lactate dehydrogenase (LDH) converts pyruvate in lactate. Shown are also the biosynthetic pathways that originate from glycolytic intermediates.
intermediates upstream of the PK reaction that can be used as precursors for the synthesis of nucleotides, amino acids, and fatty acids (Fig. 1) (reviewed in ref. [43]). Therefore, maintaining a low PKM2 activity is particularly important for highly proliferating cells, such as many cancer cells, that require a copious supply of nucleotides, amino acids, and lipids for biomass duplication. Paradoxically, the low level of PKM2 activity in rapidly proliferating cells is associated with an increased conversion of pyruvate into lactate with concomitant generation of NAD\(^{+}\) from NADH in an enzymatic reaction catalyzed by lactate dehydrogenase A (LDHA). As NAD\(^{+}\) is consumed by glyceraldehyde-3-phosphate dehydrogenase activity in a reaction that generates 1,3-biphosphoglycerate from GAP in glycolysis (Fig. 1), an efficient regeneration of NAD\(^{+}\) is required to maintain the continuity of the glycolytic flux [44]. Therefore, it appears that pyruvate is converted into lactate to sustain high glycolytic flux, regenerating NAD\(^{+}\). Interestingly, NAD\(^{+}\) is not only required to enable glycolysis but is also needed for nucleotide and amino acid biosynthesis pathways that branch from glycolysis [26, 44–47]. Therefore, during rapid cell proliferation, an efficient enzymatic activity of LDHA provides an advantage to cells by regenerating NAD\(^{+}\).

**The Warburg effect: a novel perspective**

It has long been known that normal highly proliferating and tumor cells display the Warburg-like metabolic phenotype, which is characterized by high rate of glucose uptake and conversion to lactate under aerobic conditions [20, 44, 48]. One of the most important debates about this metabolic phenotype is that aerobic glycolysis is an inefficient metabolic pathway generating less ATP per single molecule of glucose than that generated through OXPHOS and, plainly, aerobic glycolysis cannot cope with the high cellular demand of energy required during fast cell proliferation. A number of possible explanations have been proposed to account for the Warburg metabolism of proliferating cells. One possible explanation is that aerobic glycolysis essentially generates more ATP by producing it at a faster rate than OXPHOS [25, 44]. Thus it appears that the theoretical inefficiency of energy generation of glycolysis is counterweighed by the rapid production of ATP. Additionally, an increase in glycolytic flux is believed to be advantageous for proliferating cells with high demand for reducing equivalents (such as NADPH) and cellular macromolecules (such as DNA, proteins, and lipids) [49]. This is because an accelerated glycolytic flux can lead to an accumulation of glycolytic intermediates, which can be channeled into biosynthetic pathways. For example, G6P, the first glycolytic intermediate, can be oxidized through the PPP to generate the nucleotide precursor ribose-5-phosphate and NADPH, which is used for lipid biosynthesis and scavenging of reactive oxygen species (ROS) produced during fast cell proliferation (Fig. 1) [26, 32, 50]. Similarly, DHAP and 3PG, other two glycolytic intermediates, can leave the glycolytic flux and participate in the phospholipids and serine biosynthesis pathway, respectively (Fig. 1). It is important to note, however, that these glycolytic intermediates will not accumulate and branch off into their respective biosynthetic pathways unless the final enzymatic reaction in glycolysis (the conversion of PEP into pyruvate) is slowed down. To achieve this, proliferating cells and many cancer cell types predominantly express and use PKM2, which, as discussed above, has a low PK activity and therefore is less efficient in converting PEP to pyruvate than PKM1, thereby allowing for upstream glycolytic intermediates to accumulate and branch off into biosynthetic pathways. As such, PKM2 expression and its low activity is known to promote cancer cell proliferation [36–42], although recent studies in mouse cancer models have led to opposing conclusions [51]. For example, absence of PKM2 accelerates tumor formation in a Brca1-loss-driven model of breast cancer [40], in a mouse model of medulloblastoma [52], and results in spontaneous hepatocellular carcinoma (HCC) development in aged mice [53], indicating that PKM2 negatively regulates tumorigenesis. However, other in vivo studies support the notion that PKM2 has as an oncogenic function in leukemia [54] and soft tissue sarcoma formation [55]. It therefore seems likely that the function of PKM2 in cancer development depends on the cancer type. Taken together, the findings described above support the hypothesis that increased aerobic glycolysis is a metabolic strategy to improve the availability of NADPH and metabolic substrates needed for rapid biomass synthesis during fast cell proliferation. Increases in the rates of glycolysis have also beneficial antioxidant role for cells, generating NADPH essential for protecting cells from oxidative damage driven by increased cell proliferation (Fig. 1) [44, 56].

Although the Warburg effect has now been widely accepted as an emerging hallmark of cancer, it is a distinctive feature of many highly proliferating normal cells and fulfills a number of homeostatic functions, which include brain functionality, immune responses, and tissue remodeling in embryogenesis (Fig. 2) [56–62]. Thus the Warburg-like glucose metabolism has probably evolved not only to satisfy the specific biosynthetic needs of any differentiated cell type during rapid proliferation but also to regulate cell fate and functions (Fig. 2). Because of their increased biosynthetic needs, many types of cancer cells, unlike their normal counterparts, adopt this tightly controlled metabolic strategy to support their own deregulated proliferation. Therefore, targeting enhanced glycolysis in cancer represents a worthwhile therapeutic strategy. In this
respect, it is worth noting that direct inhibition of metabolic enzymes could cause adverse cellular effects and unwanted toxicity because of their relevance to normal physiological functions, such as immunity and brain development [56–62]. Therefore, effective treatment of highly glycolytic tumors will require maintaining a delicate balance between suppressing deleterious functions of glycolytic enzymes and interfering with cellular physiology (Fig. 2). Treatments aimed at inhibiting specific isoforms of certain glycolytic enzymes, the expression of which is associated with cancer, or targeting metabolic enzymes in a deregulated metabolic pathway specific to cancer cells may have better therapeutic efficacy and reduce undesired side effects. We refer the interested readers to dedicated reviews for a detailed discussion of few examples of such metabolic inhibitors that have shown promising outcomes in animal models [35, 63–65]. Therefore, a better understanding of how the Warburg-like metabolism is regulated in normal physiological contexts could lead to more effective ways of targeting metabolic pathways without toxicity (Fig. 2).

**The Warburg effect in normal cellular functions**

**The role of the Warburg effect in stem cells**

Research on stem cell biology recently provided compelling evidence in support of a role for aerobic glycolysis in the regulation of cell differentiation in various cellular contexts (Fig. 2) [66–72]. During the cellular differentiation program, pluripotent embryonic stem cells (ESCs) proceed
through several stages, becoming more specialized (differentiated) at each step. Recent investigations indicate that ESCs display elevated rates of glycolysis with lactate production before differentiation and gradually shift toward OXPHOS as they mature and become terminally differentiated [66–69]. For example, Harris and colleagues [69], using embryonic Xenopus retinal tissue, demonstrated that dividing retinal progenitors are more reliant on aerobic glycolysis when compared with more differentiated cells. A similar switch from glycolytic to oxidative metabolism accompanied by increases in the expression of mitochondrial genes has been reported to be essential for the differentiation of murine ESCs to cardiomyocytes [70, 71], as well as human neuronal progenitor cells to differentiated neurons [66]. Although the exact mechanisms underlying such metabolic shift during cell differentiation is not fully clear, recent works have proposed several potential mechanisms. In the embryonic heart, immature cardiomyocytes display an open mitochondrial permeability transition pore (mPTP) and a glycolytic phenotype [72]. Pharmacologic and genetic closing of the mPTP cause structure and function maturation of mitochondria and result in accelerated cardiomyocyte differentiation, suggesting that mPTP dynamics regulate cardiomyocyte differentiation. Moreover, gene-targeting studies in mice revealed a key role for the nuclear receptor peroxisome proliferator-activated receptor-α (PPAR-α) and its cardiac-enriched coactivator protein, proliferator-activated receptor γ-coactivator (PGC)-1β, inducing the expression of mitochondrial genes and suppressing the expression of GLUT and glycolytic enzymes during cardiomyocyte maturation from fetal to adult [73].

In contrast, a metabolic switch from oxidative to glycolytic metabolism with high levels of lactate production has been found to take place during reprogramming of somatic cells to induced pluripotent stem cells (iPSCs), in vitro [74, 75]. Differentiated somatic cells are highly dependent on mitochondrial OXPHOS for energy production and need a switch to glycolysis when they enter a pluripotent state through reprogramming. Recent studies demonstrated that such switch, which is accompanied by an upregulation of glycolytic genes, precedes the expression of pluripotent genes during the reprogramming [74, 75]. This suggests that a Warburg-like metabolic phenotype is important for the acquisition of pluripotency, the ability of a stem cell to differentiate into any cell type of the adult body. In line with this, inhibition of glycolysis via various pharmacologic means attenuates the somatic cell reprogramming to iPSC, whereas the induction of aerobic glycolysis enhances the efficiency of iPSC generation [74–77]. Thus it appears that an increase in glycolysis accompanied by a low mitochondrial activity drives the somatic cell reprogramming process. Mechanistically, two transcription factors, hypoxia-inducible factors (HIFs) and c-Myc, the main positive regulators of aerobic glycolysis in cancer [13, 21, 30], have emerged as factors essential for the maintenance and acquisition of a pluripotent state [76, 77]. Taken together, the findings described above indicate that shifts between glycolysis and mitochondrial OXPHOS are intertwined with cell differentiation and reprogramming to pluripotency.

The role of the Warburg effect in the immune response

Similar to cancer cells, inflammatory immune cells such as M1 type macrophages, neutrophils, and dendritic cells exhibit a metabolic shift to glycolysis when activated through Toll-like receptors (TLRs) upon pathogen recognition [56–61, 78]. This leads to the production of various pro-inflammatory cytokines including interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α). This metabolic shift involves an increase in the expression of GLUT1 (SLC2A1) gene and specific glycolytic genes as well as elevated lactate production accompanied by a decline in mitochondrial activity. Additionally, flux into the PPP, which allows the synthesis of nucleotides and NADPH generation, also enhances [57, 58, 79, 80]. It is now appreciated that the glycolytic metabolism allows mature activated immune cells to sustain rapid ATP production and satisfy the high demand of biosynthetic precursors associated with an acute inflammation or antibacterial response. Indeed, unlike cancer cells, activated immune cells are not highly proliferative, implying that a high proliferation rate is not the only explanation for why aerobic glycolysis is selected for in immune cells upon TLR activation [78]. In TLR-activated macrophages, for example, this metabolic choice may reflect the important role of mitochondrial ROS (mROS) in their bactericidal activity [58, 81, 82]. mROS are generated when electrons prematurely exit the electron transport chain and incompletely reduces oxygen to form superoxide (O$_2^-$), thus compromising the mitochondrial synthesis of ATP. It seems, therefore, that one potential benefit of favoring glycolysis over mitochondrial OXPHOS for ATP production would be to compensate for reduced mitochondria ATP production as mitochondria is used to produce ROS for the clearance of intracellular bacteria [58, 81, 82]. More recently, the metabolic shift toward the glycolytic pathway has been shown to be essential for the migration of activated macrophages to the sites of inflammation. Pharmacological inhibition of the glycolytic pathway or uptake of glucose suppresses the migration of murine macrophages to inflamed tissue. Moreover, PKM2 was found to localize in filopodia and lamellipodia, two cytoskeleton structures essential for cell migration [83]. This indicates that glycolysis is positively associated with the migratory properties of macrophages.
The important role for the glycolytic pathway in immune responses was also revealed by studies on T cells that carry the CD4 antigen. In the presence of specific cytokine microenvironment, this specialized population of T cells (CD4+ T cells) become activated and can differentiate into either effector T cells (Teffs) or regulatory T cells (Tregs) following the engagement of the T-cell antigen receptor (TCR) and co-stimulatory receptors [59, 60]. Whereas Teffs, which include T helper type 1 (Th1), Th2, and Th17 cell subset, are involved in the inflammatory responses, induced Tregs (iTregs) limit inflammation and possess immunoregulatory functions [59, 60]. It is now clear that Teffs and iTregs adopt distinct metabolic programs to attain their opposing functions, with Teffs expressing high surface levels of the GLUT1 and being highly glycolytic, whereas Tregs express low levels of GLUT1 and exhibit oxidative metabolism [84]. Importantly, inhibition of glycolysis has been shown to block the development of Th17 cell subset and at the same time to promote Tregs generation, indicating that glycolysis is crucial for controlling T cell lineage choices [58, 85, 86]. Moreover, glycolysis is not required to promote proliferation and survival of T cells but is needed instead for T cell migration and effector functions as well as antitumor immunity [58, 60, 87].

The close relationship between glycolysis and antitumor immunity has received considerable attention in the past few years since the reported success of adoptive T cell immunotherapy [88]. Insufficiency of glucose in the tumor microenvironment caused by high rates of glucose uptake in tumor cells has been shown to suppress the antitumor response of tumor-infiltrating T cells, indicating a mechanism by which glycolytic metabolism of tumor cells directly suppresses the antitumor T cell function. More importantly, enforcing the production of the glycolytic metabolite PEP in such suppressed infiltrating T cells restored the effectiveness of their antitumor responses, which resulted in suppression of tumor growth upon adoptive transfer [89]. Thus glycolysis seems to have an important contribute in the choice between pro-inflammatory and anti-inflammatory CD4+ T cell subsets and their antitumor functions. As such, manipulating the glycolytic pathway in tumor and/or T cells may be beneficial in enhancing the efficacy of adoptive cancer immunotherapy. Along these lines, the swift to glycolysis has also been shown to be a critical event in M1 and M2 macrophage polarization, a tightly controlled process by which macrophages acquire distinct phenotypes and functional capabilities in response to diverse tissue-derived microenvironmental signals [90]. While M1 macrophages have an inflammatory phenotype with a strong antimicrobial and antitumor activity, M2 macrophages prevent excess inflammation and promote tissue repair and remodeling as well as antiparasitic immunity and tumor progression [91]. It is worth noting that a shift in the balance between these polarization states of macrophages is central to a spectrum of human diseases, including obesity and cancer. For example, diet-induced obesity has been shown to be a consequence of an inappropriate accumulation of proinflammatory M1 state in the adipose tissue that leads to insulin resistance [92], whereas chronic weight loss was found to result from an excess presence of M2 macrophages in the adipose tissue [93]. Moreover, a high density of tumor-associated macrophages, which closely resemble the M2 state, has been shown to associate with tumor progression and poor prognosis in various tumour types [94]. Interestingly, inflammatory M1 macrophages favor glycolysis over mitochondrial OXPHOS for rapid pathogen killing, whereas anti-inflammatory M2 macrophages use OXPHOS as the main ATP-producing pathways [58, 60]. As such, blocking mitochondrial ATP production with oligomycin resulted in phenotypic repolarization of M2 to M1 cells [95]. Therefore, broader understanding of the metabolic features of M1 and M2 macrophages could indicate new targets for manipulating macrophage polarization in a therapeutic context. Taken together, the findings described above illustrate the importance of the Warburg effect in promoting the effector functions of immune cells (Fig. 2). Importantly, the signaling mechanisms that regulate aerobic glycolysis are the subject of intense ongoing research. Several studies showed that activation of certain signaling pathways, such as ERK and JNK pathways, can directly or indirectly affect the transcriptional or posttranscriptional regulation of enzymes involved in glycolysis and OXPHOS as well as their anabolic pathway branches. A stepwise description of the roles of these two MAPK pathways in promoting the Warburg effect is outlined in the following sections.

The ERK signaling and the Warburg effect

In addition to their recognized role in controlling cell proliferation and survival, many of the signaling pathways downstream of both oncogenes and tumor-suppressor genes can regulate the glucose metabolism [6, 32]. For example, the ERK-MAPK signaling pathway, which is activated by the RAS oncoproteins (HRAS, KRAS, and NRAS) and positively associated with cell proliferation and survival [23, 24], has been shown to promote the Warburg effect [96]. Like other MAPK signaling pathways, the ERK pathway is activated by a series of phosphorylation events (i.e., the MAPK model) that occur downstream of a variety of activated receptor types including RTKs in response to extracellular stimuli such as growth factors (Fig. 3). The initiating kinases (i.e., the MAP3K) are members of the RAF family, which include ARAF, BRAF, and CRAF, and often activated as a result of their interaction with active
GTP-bound RAS proteins. This interaction, which occurs at the inner leaflet of the plasma membrane, leads to the formation of active homodimers or heterodimers of the RAF protein kinases (Fig. 3). Once activated, RAF kinases phosphorylate and activate components of the MAP2K module, such as MEK1 and MEK2, which in turn, activate the two MAPK protein kinases, ERK1 and ERK2, through phosphorylation of both tyrosine and threonine residues present in a conserved tripeptide motif (Thr-Glu-Tyr) within their activation loop. Upon activation, ERK1 and ERK2 phosphorylate and activate a large number of nuclear and non-nuclear proteins, including transcription factors of the ETS family, the ternary complex factor transcription factors, c-Myc, signal transducer and activator of transcription factor 3, nuclear factor (NF) of activated T cells, as well as cell survival regulators of the BCL-2 protein family in the context of aerobic glycolysis by ERK and JNK signaling pathways in proliferating cells.
mitochondria [23, 24]. These proteins regulate a diversity of cellular processes, such as cell proliferation, growth, survival, differentiation, and motility, whose deregulation has been associated with cancer [23, 24, 97]. Indeed, constitutive activation of ERK1 and ERK2 signaling is frequently observed in human cancers due to mutations in genes that encode RTKs, RAS, BRAF, CRAF, MEK1, and MEK2 [24, 98]. In melanoma, for example, up to 70% of these tumors have point mutations in the BRAF gene, the majority of which lead to a single amino acid substitution of valine for glutamic acid at position 600 (the BRAFV600E mutation). These mutations favor the active structural conformation of BRAF kinase, causing the constitutive activation of ERK1/2 pathway, which then activates proliferative programs and promotes the aerobic glycolytic phenotype via induction of transcriptional regulators of glycolysis, the TCA cycle, and macromolecular biosynthesis (Fig. 3) [98]. Among these transcription factors are c-Myc, which increases the expression of GLUT1, LDHA, and a number of enzymes in the glycolytic pathway, as well as HIF-1α, which also upregulates LDHA and cooperates with c-Myc in the induction of HK2 [99–101]. c-Myc is also known to induce expression of enzymes involved in nucleotide and fatty acid synthesis as well as glutaminolysis, which sustains the pool of metabolic intermediates in the TCA cycle that in turn can be used as biosynthetic precursors to generate amino acids and fatty acids for anabolic growth [102–104]. Moreover, c-Myc facilitates the glycolytic intermediates flux to the PPP, serine, and glycine biosynthesis pathways by promoting PKM2 expression [105]. In line with this, enforced expression of BRAF(V600E) in melanoma cells has been shown to upregulate the expression of glycolytic and PPP enzymes to sustain melanoma cell growth and proliferation [106]. Interestingly, Haq and collaborators [107] observed that BRAF(V600E) expression in melanomas correlates with decreased expression of oxidative enzymes, diminished mitochondrial number and function, and increased production of lactate. The authors also showed that activated BRAF/ERK pathway promotes glycolytic phenotype in melanoma cells by downregulating the expression of the mitochondrial biogenesis and function factor, PGC-1α, thereby inhibiting the mitochondrial oxidation [107].

In addition, high levels of serum lactate were observed in patients with BRAF mutant melanomas [108], providing evidence of linking oncogenic BRAF/ERK signaling to aerobic glycolysis in a clinical setting. Activating mutations in the BRAF gene have also been identified in non-melanoma tumors, including thyroid, colorectal carcinomas, lung cancer, and hairy cell leukemia [109], and were linked to the glycolytic phenotype in both in vitro and in vivo cancer models [110, 111].

The link between the Warburg effect and the RAF/MEK/ERK pathway was further confirmed by cellular and xenograft studies using BRAF inhibitors or MEK inhibitors. A decrease in the expression levels of various glycolytic genes, including GLUT1, GLUT3, and HK2, lactate and ATP production was observed in a panel of BRAF(V600E) melanoma cell lines treated with the BRAF inhibitor vemurafenib as well as in samples from patients undergoing BRAF inhibitor therapy. Such effect was associated with a decrease in the transcription of ERK1/2 target genes [97]. Importantly, treatment of vemurafenib-resistant BRAFV600E melanoma cells with vemurafenib in combination with the pyruvate mimic dichloroacetate, which inhibits glycolysis as a consequence of an increase in glycolysis-derived pyruvate flux into the TCA cycle [112], was shown to restore the expression of glycolytic enzymes and re-sensitize these resistant cells to vemurafenib [98], indicating that glycolysis contributes to resistance to BRAF/MEK/ERK pathway inhibition in melanoma. A decrease in glucose uptake, lactate levels, and HK2 expression was also observed in human cancer cells harboring mutant BRAF and BRAF-driven melanoma xenografts following MEK1/2 inhibition [113], confirming a positive correlation between the glycolytic phenotype of cancer cells and BRAF/MEK/ERK pathway activation.

An important role of ERK1/2 signaling in promoting the Warburg-like metabolism can also be inferred from studies in other oncogenic contexts. DePinho and colleagues [114], using an inducible mouse model of pancreatic cancer driven by the Kras oncogene, demonstrated that oncogenic activation of the RAF/MEK/ERK pathway sustains tumor growth by inducing transcriptional upregulation of key genes that promote both the uptake and consumption of glucose to produce lactate, resulting in an increase in glycolytic intermediates flux into anabolic pathways, such as the hexosamine and non-oxidative PPP pathways, which provide precursors for protein glycosylation and nucleotide biosynthesis. The ERK-directed transcriptional program was found to be dependent on c-Myc transcriptional activity, providing further evidence linking the ERK1/2 signaling to the Warburg-like metabolism in cancer cells [114]. Another intriguing link between the ERK1/2 signaling and cancer-associated Warburg effect is provided by the glycolytic enzyme phosphoglycerate kinase 1 (PGK1) [115]. Activation of ERK1/2 by hypoxia, epidermal growth factor (EGF) stimulation, mutant BRAF, or KRAS was shown to induce mitochondrial translocation of PGK1, through phosphorylation of S203. This phosphorylation event in turn results in phosphorylation and activation of pyruvate dehydrogenase kinase (PDK), of which there are four isoforms (PDK1–4) [115]. Upon activation, PDK1 inhibits the enzyme complex pyruvate dehydrogenase (PDH), which converts pyruvate into acetyl-CoA (the main substrate for
the TCA cycle), resulting in the suppression of pyruvate consumption and ROS production in mitochondria and increased lactate production. Thus, by promoting PGK1 mitochondrial translocation, ERK1/2 enhances aerobic glycolysis and compromises the TCA cycle, resulting in brain tumorigenesis (Fig. 3) [115]. In another study, however, oncogenic activation of ERK1/2 was shown to positively regulate TCA cycle flux (via PDH) by suppressing the PDK4 expression. The positive regulation of PDH flux by ERK1/2 signaling was associated with an increase in cell proliferation rates [116]. Given that the TCA cycle supplies substrates for energy production by OXPHOS and intermediates for lipid and amino acid synthesis [32, 103], these contrasting findings probably reflect the fact that proliferating cells modulate PDH flux through ERK1/2 signaling to suit distinct metabolic needs of each specific cell type.

Besides affecting metabolic enzymes, ERK1/2 pathway can also influence cellular metabolism indirectly by controlling the AMP-activated protein kinase (AMPK), a key regulator of energy homeostasis that is activated under low-energy conditions by the tumor-suppressor liver kinase B1 (LKB-1) in most cellular contexts [117]. Upon activation, AMPK inhibits almost all biosynthetic pathways needed for cell proliferation to decrease ATP consumption and activates ATP-producing catabolic pathways, thus allowing cells to restore energy homeostasis [117]. Although activated AMPK has been shown to enhance glucose uptake and glycolysis in certain contexts [118], mouse embryo fibroblasts or cancer cells lacking AMPK activity exhibit an elevated glucose consumption and lactate production associated with increased lipid biosynthesis and ability to form tumors in vivo [119, 120]. Mechanistically, the transcription factor HIF-1α has been shown to be required for increased glycolysis and biosynthesis observed in AMPK-deficient cells. In line with recent studies in human gastric cancer cell [121], these observations suggest that AMPK can suppress the Warburg-like metabolism that underpins tumorigenesis. In support of this view, downregulation of LKB1-AMPK signaling by oncogenic signaling pathways that promote the Warburg-like phenotype has been reported in many cancers [119]. In BRAF(V600E) melanoma cells, for example, activated ERK has been shown to phosphorylate LKB1, rendering this enzyme unable to bind to and activate AMPK [122, 123] (Fig. 3). The inactivation of LKB1 by ERK has been shown to be instrumental in BRAF(V600E)-driven tumorigenesis. The inhibition of the LKB1-AMPK axis by ERK was also shown to promote cell growth and proliferation in other highly glycolytic cancers [123], providing further evidence linking ERK1/2 signaling to the metabolic features of cancer cells.

Constitutive activation of ERK1 and ERK2 by mutational activated RTKs, such as the EGF receptor mutant III (EGFRvIII), also leads to the Warburg effect phenotype. Lu and colleagues [96] demonstrated that EGFR-activated ERK1/2 binds to and phosphorylates PKM2 at Ser37 favoring its nuclear translocation (Fig. 4). Importantly, ERK1/2 phosphorylates PKM2, but not PKM1, leading to Pin1-dependent cis-trans isomerization and conversion of PKM2 from a tetramer to a monomer. In the nucleus, PKM2 couples with transcriptional factors and functions as a protein kinase that phosphorylates histone H3 for gene transcription of cyclin D1 and c-Myc, which promotes the expression of glycolytic enzyme genes (Fig. 4) [96].

However, it is worth noting that c-Myc not only promotes glycolysis but also favors mitochondrial respiration by enhancing the expression of genes involved in mitochondrial structure and biogenesis [104, 124–126]. Indeed, knockdown of c-Myc in breast cancer cells with stem-like features was found to be associated with decreases in mitochondrial mass and oxygen consumption as well as in the number of mitochondria. The impaired mitochondrial function was associated with reduced mammosphere formation, which is an assay method to test “stemness” of cancer cells in vitro and tumor initiation in vivo [127, 128]. Thus both glycolysis and OXPHOS appear to be positively regulated by c-Myc and essential for tumorigenesis. As a whole, these examples illustrate that oncogenic alterations in ERK1/2 signaling pathway, which has a crucial role in sustaining proliferative programs, determine a metabolic switch from mitochondrial metabolism to glycolysis in cancer cells, fulfilling the energetic and biosynthetic requirements for tumor growth. As such, several therapeutic approaches targeting this pathway at multiple levels are currently being tested in clinical trials or used in the clinic for cancer treatment [129], and their efficacy have been correlated with the inhibition of glycolysis and/or anabolic metabolism [130–132].

There is also striking evidence that ERK1/2 activation is critical for the switch from OXPHOS to glycolysis observed in activated T cells that, as discussed above, is essential for T cell effector differentiation and function. Indeed, pharmacologic inhibition of ERK1/2 activity blocked the increase in glucose uptake and glycolysis as well as mRNA expression and activity of the glycolytic enzyme HK induced by the ligation of the TCR and the co-stimulatory receptor CD28 [133]. Furthermore, inhibition of ERK1/2 has been shown to impair glucose consumption and lactate production in macrophages activated by LPS. Mechanistically, the decrease in glycolysis appears to be related to the reduction in the levels of the glycolytic intermediate fructose-2,6-bisphosphate (F2,6BP) [134], an allosteric activator of the glycolytic enzyme PFK1 [6]. Thus, by enhancing glycolysis, ERK1/2 signaling positively controls T cell and pro-inflammatory macrophage function.
Fig. 4 ERK- and JNK-mediated phosphorylation of PKM2 is at the crossroad between proliferation and apoptosis. PKM2 acts as master regulator of the Warburg effect. Of the many posttranslational modifications, phosphorylation of PKM2 by either ERK or JNK1 dictates distinct outcomes. In quiescent cells, PKM2 is present as a tetrameric protein associated with elevated enzymatic activity. When cells receive a growth stimulus, activation of ERK drives phosphorylation of tetrameric PKM2. Phosphorylated PKM2 is then cis-trans isomerized by PIN1 allowing dissociation of tetrameric PKM2 to monomers. Monomeric PKM2 enters the nucleus where it acts as histone-binding protein allowing gene expression regulation of both glycolytic enzymes and cell cycle regulators (i.e., c-Myc, cyclin D1). Besides, accumulation of reactive oxygen species (ROS) in the cytoplasm promotes activation of JNK1, which can phosphorylate and enhance PKM2 activation, allowing cells to reduce their antioxidant capacity and induce apoptosis. Notably, enhanced expression of PARP14 in cancer cells suppresses JNK1-mediated phosphorylation and activation of PKM2, providing therefore survival advantages to cancer cells. PARP14 by suppressing JNK1 activity contributes to maintain low PKM2 activity and, combined with a robust glycolysis, leads to an accumulation of glycolytic intermediates, including precursors of nucleic acids, lipids, and amino acids. This accumulation provides a metabolic bottleneck allowing glycolytic intermediates to be redirected toward biosynthesis, fueling through the pentose phosphate pathway for DNA synthesis and thereby contributing to the rapid cell proliferation seen in tumors.
The JNK signaling and the Warburg effect

Another MAPK subfamily mechanistically linked to the Warburg effect is the JNK kinase family [102], which includes three proteins (JNK1, JNK2, and JNK3) that are encoded by three separate genes, namely, jnk1 (mapk8), jnk2 (mapk9), and jnk3 (mapk10) [24]. Whereas JNK1 and JNK2 are ubiquitously expressed in mammalian cells, the expression of JNK3 is restricted to certain tissues [24]. The JNK proteins—also known as stressed-activated protein kinases—are activated by a variety of extracellular stimuli, including stress, proinflammatory cytokines, growth factors, pathogens, toxins, and drugs. Similarly to ERK1/ERK2, activated JNKs can directly phosphorylate a variety of cytoplasmic and nuclear substrates, which participate in a diversity of cellular processes, including proliferation, differentiation, apoptosis, and survival [135].

It is now appreciated that the functions of each JNK protein can either differ or overlap depending on the cell type [135]. With respect to cancer, for example, JNK2 appears to be a crucial tumor promoter of carcinogen-type [135]. With respect to cancer, for example, JNK2 proteins can either differ or overlap depending on the cell type [139]. Thus JNK proteins play different and even opposing roles in cancer development, although functional redundancy between JNK1 and JNK2 has also been reported [135]. Support evidence for the latter stems from studies showing that loss of either JNK1 or JNK2 has no effect on development of B lymphomas induced by transgenic expression of the c-Myc oncogene and overall survival rate of c-Myc-transgenic mice, thus promoting the tumorigenicity of glioblastoma cells [138]. Conversely, JNK1 is required for proliferation of hepatocytes and liver cancer cells in vivo, while JNK2 appears to be dispensable [139]. Thus JNK proteins play different and even opposing roles in cancer development, although functional redundancy between JNK1 and JNK2 has also been reported [135]. Support evidence for the latter stems from studies showing that loss of either JNK1 or JNK2 has no effect on development of B lymphomas induced by transgenic expression of the c-Myc oncogene and overall survival rate of c-Myc-transgenic mice, thus indicating that loss of one JNK protein is compensated for by the other remaining [140]. Redundant or partially redundant roles for JNK1 and JNK2 proteins have also been identified in studies of Burkitt’s lymphoma [137, 141] and breast cancer cell lines, as well as mouse models of breast cancer caused by loss of a single allele of the p53 tumor-suppressor gene [142, 143]. While the findings outlined above indicate that JNK proteins can play roles in tumor development, they also emphasize that JNK1 and JNK2 have either distinct or redundant functions. Whether JNK1 and JNK2 differentially affect cancer-associated metabolic changes is a matter of active investigation.

Despite a connection between JNKs and metabolic disorders (i.e., obesity-induced immune cell recruitment, inflammation in adipose tissue, insulin resistance, impaired glucose homeostasis) in mammalians have been widely described (reviewed in ref. [144]), very little is known about possible links between the JNK pathway and the metabolic reprogramming of tumor cells. Recent work from our group as well as several other laboratories revealed a role for the JNK pathway in restraining aerobic glycolysis to promote apoptosis in cancer cells [145]. In HCC cells, for example, JNK1 activity is suppressed by the antiapoptotic protein poly(ADP-ribose) polymerase 14 (PARP14), and this suppression appears to be the key determinant for the Warburg-like phenotype needed for enhanced HCC cell survival [146]. The inhibition of JNK1 by PARP14 was also shown to support antioxidant capacity of HCC cells by increasing NADPH and glutathione levels. At a mechanistic level, JNK1 stimulates PKM2 activity by enhancing the affinity of PKM2 for its substrates, PEP and ADP, through phosphorylation of Thr365.

This function of JNK1 seems to be one of possible mechanisms underlying the anti-Warburg effect and apoptotic role of JNK1 in cancer (Fig. 4) [146].

Moreover, it was shown that activation of the JNK pathway by the histone methyltransferase inhibitor chaetocin, which induces apoptosis in cancer cells by inducing ROS production, resulted in a reduction of glucose uptake and lactate production in glioma cells [147]. Although the mechanisms have not been explored in depth, JNK activation in glioma cells following chaetocin treatment led to a marked increase in PK activity and decrease of HK2 activity and expression [147], implying a role for the JNK pathway in restraining the glycolytic metabolism in glioma cells. Importantly, culturing cancer cells with elevated concentrations of pyruvate increased the activity of JNK1, but not JNK2, by enhancing ROS production [148]. Mechanistically, it was shown that activation of the ROS→JNK1 axis activates the ribosomal kinase p70S6K, which in turn suppresses glycolysis partly and results in increased augmented activity of glycolytic synthase, an enzyme involved in converting glucose to glycogen, and subsequent diverting glucose away from the mitochondria [148]. Likewise, glutamine deprivation in osteosarcoma cells stimulates endoplasmic reticulum stress, which leads to the activation of JNK by inducing transcription and secretion of IL-8, needed for osteolysis associated with metastatic breast cancer [149]. Altogether these observations suggest the JNK pathway is involved in the regulation of cellular metabolism in cancer cells. In addition to cancer cells, JNK1 has been shown to suppress glycolysis in normal tissue. Knockdown of JNK1 in normal liver cells upregulated the hepatic expression of clusters of genes involved in glycolysis and in triglyceride synthesis pathways, suggesting that basal activity of JNK1 negatively regulates hepatic glycolysis and biomass formation [150]. This was further confirmed by studies using high-fat-fed mice with compound deficiency of JNK1 and JNK2 in hepatocytes, which exhibited increased expression of glycolytic enzymes and lactate production accompanied by a reduced rate of mitochondrial oxygen consumption. Such effects of JNK1 and
JNK2 deletion were associated with an upregulation of genes involved in the PPAR, leading to marked increases in the rate of fatty acid oxidation, ketogenesis, and improved hepatic insulin action in these mice. This indicates that JNK1 and JNK2 in hepatocytes function to reduce glycolysis, fatty acid oxidation, and ketogenesis in response to a high-fat diet [151].

However, in the literature there are also examples where activation of the JNK signaling drives aerobic glycolysis, instead of inhibiting it. Deng et al. [152] reported that JNK1-mediated phosphorylation of Bad (a BH3-only pro-apoptotic Bcl-2 family protein) is required for glycolysis through activation of PFK1. Genetic disruption of Jnk1 alleles or silencing of Jnk1 by small interfering RNA abrogates glycolysis induced by growth/survival factors, such as serum or IL-3 [152]. Furthermore, activation of JNK in cortical neurons has been shown to suppress pyruvate metabolism in mitochondria and promote pyruvate conversion to lactate in the cytosol by phosphorylating and inhibiting the PDH complex that normally converts pyruvate to acetyl-CoA, which can then enter into TCA cycle (Fig. 3) [6]. Thus, by inhibiting PDH, the activity of JNK in cortical neurons compromises the oxidative metabolism and favors glycolysis (via lactate production with concomitant NAD+ regeneration) [153]. Of note, like PKM2, PDH is a specific substrate of JNK1 [153]. Activation of the JNK pathway has also been shown to mediate the pro-glycolytic effect of oncogenic RAS expression in primary human keratinocytes. Indeed, keratinocyte-overexpressing RAS mutant exhibited a marked increase in the rate of glycolysis compared to control cells. Such effect was abolished in these cells by treatment with several JNK inhibitors, such as SP600125, indicating that JNK activity plays a central role in RAS-induced glycolysis [154].

In conclusion, the information outlined here indicate that JNK signaling (more likely JNK1) acts as negative regulator of aerobic glycolysis in different types of glycolytic tumors, suggesting an intricate link between JNK and cellular metabolism. These studies also provide evidence for JNK regulating an inextricable crosstalk between apoptosis and cancer metabolism and opens up an interesting opportunity to explore the importance of understanding both the functional roles of each JNK protein in the context of tumor metabolism, in order to validate the therapeutic potential of JNK inhibition in cancer. As pointed out earlier, restraining of the JNK signaling is a common trait of glycolytic tumors [146, 147]. Likewise, survival of many tumors relies on the constitutive activation of the transcription factor NF-κB, which restrains JNK-mediated apoptosis (reviewed in ref. [155]). It would be interesting to understand whether cancers highly dependent on NF-κB activity are more glycolytic than tumors with less active NF-κB. Or whether any of the NF-κB-regulated genes (suppressing JNK signaling) are key regulators of aerobic glycolysis in cancer cells. Notably, NF-κB-mediated restraining of JNK-induced apoptosis is also a mechanistic phenotype activated in response to pro-inflammatory cytokines (i.e., TNF-α) (reviewed in ref. [155]). In this regard, it is imperative querying whether enhanced JNK activation observed in response to TNF-α in NF-κB-deficient cells is associated with inhibition of aerobic glycolysis. Of particular attention are also many examples in the literature in regard to JNK driving aerobic glycolysis. Therefore, future studies aimed at a better understanding of JNK signaling in the regulation of inflammation, cell metabolism, and cancer will likely translate the biology of JNK signaling into a program of drug discovery for inflammatory, metabolic, and cancer diseases.

Conclusions and future perspectives

A common characteristic of cancer cells that distinguish them from their normal counterparts is an increase in glycolysis with concomitant lactate production (the Warburg effect) [6, 7, 11, 12]. This observation has led to intensive studies of both the molecular mechanisms underlying the Warburg effect and its cellular function with the goal of identifying targeted therapies that are selectively cytotoxic to cancer cells while preserving normal tissue. However, efforts to translate this knowledge into effective therapy is still underway and to date very few drugs targeting the Warburg effect have been approved for clinical evaluation [63, 64]. The main limitations can be surmised as: (1) the metabolic phenotype of cancer cells is also shared by untransformed rapidly proliferating cells, especially cells of the immune system; (2) most glycolytic enzymes are ubiquitously expressed in all mammalian cells and direct targeting of those enzymes could have detrimental side effects. Therefore, targeting oncogenic signaling pathways that affect cellular metabolism may overcome in part limitations of direct targeting of metabolic enzymes. Currently, there are several therapeutic strategies being used to target upstream regulators of metabolic pathways, such as PI3K, AKT, and HIF-1α signaling module [21, 64]. Yet, these targets are also generally shared by normal cells, compromising the development of safe and efficient inhibitors for cancer therapy. Therefore, the identification of pathways that are solely activated in different tumor types is still the best approach to identify drugs against targets that are efficacious and specific for tumors with minimal toxicity on normal cells. In this regard, the BRAF/MEK/ERK pathway represents an ideal candidate for targeting both oncogene and metabolism of certain types of tumors, especially melanomas [98, 106–109], or may work successfully as a combinatorial regimen with other anticancer drugs [109, 129, 130]. Conversely, activating JNK1 that suppresses aerobic glycolysis and favors apoptosis may provide...
additional therapeutic avenues for glycolytic cancers exhibiting low basal JNK activity, including inflammation-driven cancers (i.e., HCC and multiple myeloma [135, 155]. In this respect, it is important to note that inhibition of either PARP14 or NF-κB activity may achieve inhibition of tumor metabolism via activation of JNK activity [135, 155]. Further studies into this aspect of cancer cell biology will help to identify targets that will inhibit certain signaling pathways while preserving others and therefore will conceive more efficient antineoplastic agents.

Acknowledgements The authors acknowledge the research funding from Brunel Research Initiative & Enterprise Fund, Brunel University of London (to CB), Kay Kendall Leukemia Fund (KKL443) (to CB), 250 Great Minds Fellowship, University of Leeds (to SP), AMMF of London (to CB), Kay Kendall Leukemia Fund (KKL443) (to CB), from Brunel Research Initiative & Enterprise Fund, Brunel University (to CB), and Bloodwise (to SP and PMC). Additional funding was provided by the Cholangiocarcinoma Charity (to SP and PMC), and Bloodwise (to SP and PMC).

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Lusk G. The elements of the science of nutrition. 2nd ed. Philadelphia: W.B. Saunders Co.; 1909.
2. Blaxter K. Energy metabolism in animals and man. Cambridge: Cambridge University Press; 1989.
3. Lehninger AL, Nelson DL, Cox MM. Principles of biochemistry. 2nd ed. Worth, New York: Worth; 1993.
4. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029–33.
5. Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell. 2008;134:703–7.
6. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer. 2011;11:85–95.
7. Warburg O. On the origin of cancer cells. Science. 1956;123:309–14.
8. Hedeskov CJ. Early effects of phytohaemagglutinin on glucose metabolism of normal human lymphocytes. Biochem J. 1968;110:373–80.
9. Munyon WH, Merchant DJ. The relation between glucose utilization, lactic acid production and utilization and the growth cycle of L strain fibroblasts. Exp Cell Res. 1959;17:490–8.
10. Pouysségur J, Franchi A, Silvestre P. Relationship between increased aerobic glycolysis and DNA synthesis initiation studied using glycolytic mutant fibroblasts. Nature. 1980;287:445–7.
11. Ferreira LM, Hebrant A, Dumont JE. Metabolic reprogramming of the tumor. Oncogene. 2012;31:3999–4011.
12. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4:891–9.
13. Dang CV, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res. 2009;15:6479–83.
14. Levine AJ, Puzio-Kuter AM. The control of the metabolic switch in cancers by oncopogenes and tumor suppressor genes. Science. 2010;330:1340–4.
15. Taha C, Liu Z, Jin J, Al-Hasani H, Sonenberg N, Klip A. Opposite translational control of GLUT1 and GLUT4 glucose transporter mRNAs in response to insulin. Role of mammalian target of rapamycin, protein kinase b, and phosphatidylinositol 3-kinase in GLUT1 mRNA translation. J Biol Chem. 1999;274:33085–91.
16. Wieman HL, Wofford JA, Rathmell JC. Cytokine stimulation promotes glucose uptake via phosphatidylinositol-3 kinase/Akt regulation of Glut1 activity and trafficking. Mol Biol Cell. 2007;18:1437–46.
17. Miyamoto S, Murphy AN, Brown HJ. Akt mediates mitochondrial protection in cardiomyocytes through phosphorylation of mitochondrial hexokinase-II. Cell Death Differ. 2008;15:521–9.
18. Gottlob K, Majewski N, Kennedy S, Kandel E, Robey RB, Hay N. Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev. 2001;15:1406–18.
19. Kroemer G, Pouysségur J. Tumor cell metabolism: cancer’s Achilles’ heel. Cancer Cell. 2008;13:472–82.
20. Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell. 2008;134:703–7.
21. Dang CV, Kim JW, Gao P, Yustein J. The interplay between MYC and HIF in cancer. Nat Rev Cancer. 2008;8:51–56.
22. Jones RG, Thompson CB. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev. 2009;23:537–48.
23. Cargnelllo M, Roux PP. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev. 2011;75:50–83.
24. Raman M, Chen W, Cobb MH. Differential regulation and properties of MAPKs. Oncogent. 2007;26:1000–12.
25. Locasale JW, Cantley LC. Metabolic flux and the regulation of mammalian cell growth. Cell Metab. 2011;14:443–51.
26. Hosios AM, Vander Heiden MG. The redox requirements of proliferating mammalian cells. J Biol Chem. 2018;293:7490–8.
27. Ward PS, Thompson CB. Signaling in control of cell growth and metabolism. Cold Spring Harb Perspect Biol. 2012;4:a006783.
28. Lim SO, Li CW, Xia W, Lee HH, Chang SS, Shen J, et al. EGFR signaling enhances aerobic glycolysis in triple-negative breast cancer cells to promote tumor growth and immune escape. Cancer Res. 2016;76:1284–96.
29. Vander Heiden MG, Plas DR, Rathmell JC, Fox C, Harris MH, Thompson CB. Growth factors can influence cell growth and survival through effects on glucose metabolism. Mol Cell Biol. 2001;21:5899–912.
30. Lum JJ, Bui T, Gruber M, Gordan JD, DeBerardinis RJ, Covello KL, et al. The transcription factor HIF-1alpha plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis. Genes Dev. 2007;21:1037–49.
31. Elstrom RL, Bauer DE, Buzzi M, Karnauskas R, Harris MH, Plas DR, et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 2004;64:3892–9.
32. Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23:27–47.
The ERK and JNK pathways in the regulation of metabolic reprogramming

33. Barthel A, Okino ST, Liao J, Nakatani K, Li J, Whitlock JP Jr, et al. Regulation of GLUT1 gene transcription by the serine/threonine kinase Akt1. J Biol Chem. 1999;274:20281–6.

34. John S, Weiss JN, Ribalet B. Subcellular localization of hexokinases I and II directs the metabolic fate of glucose. PLoS ONE. 2011;6:e17674.

35. Dayton TL, Goecheva V, Miller KM, Bhuktar A, Lewis CA, Bronson RT, et al. Isoform-specific deletion of PKM2 constrains tumor initiation in a mouse model of soft tissue sarcoma. Cancer Metab. 2018;6:6.

36. Christofk HR, Vander Heiden MG, Wu N, Asara JM, Cantley LC. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature. 2008;452:181–6.

37. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumor growth. Nature. 2008;452:230–3.

38. Cortés-Cros M, Hemmerlin C, Ferretti S, Zhang J, Gounarides J, Lisanti MP. Cancer metabolism: a therapeutic perspective. Nat Rev Cancer. 2016;16:635–55.

39. catalog of cancer metabolism. Cell. 2012;148:409–16.

40. Chang CH, Curtis JD, Maggi LB Jr, Faubert B, Villarino AV, O’Sullivan D, et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell. 2013;153:1239–51.

41. Lunt SY, Muralidhar V, Hosios AM, Israelsen WJ, Gui DY, Newhouse L, et al. Pyruvate kinase isoform expression alters nucleotide synthesis to impact cell proliferation. Mol Cell. 2015;57:95–107.

42. Goyal MS, Hawrylycz M, Miller JA, Snyder AZ, Raichle ME. Aerobic glycolysis in the human brain is associated with development and neotenic gene expression. Cell Metab. 2014;19:49–57.

43. Lunt SY, Vander Heiden MG. Pyruvate kinase function, regulation and role in cancer. Semin Cell Dev Biol. 2015;43:43–51.

44. Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol. 2011;27:441–64.

45. Cantó C, Menzies KJ, Auwerx J. NAD(+) metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus. Cell Metab. 2015;22:31–53.

46. Birsoy K, Wang T, Chen WW, Freinkman E, Abu-Ramah M, Sabatini DM. An essential role of the mitochondrial electron transport chain in cell proliferation is to enable aspartate synthesis. Cell. 2015;162:540–51.

47. Sullivan LB, Gui DY, Hosios AM, Bush LN, Freinkman E, Vander Heiden MG. Supporting aspartate biosynthesis is an essential function of respiration in proliferating cells. Cell. 2015;162:552–63.

48. Senyilmaz D, Telemam AA. Chicken or the egg: Warburg effect and mitochondrial dysfunction. F1000Prime Rep. 2015;7:41.

49. Liberti MV, Locasale JW. The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci. 2016;41:211–8.

50. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature. 2000;408:239–47.

51. Wiese EK, Hitisugi T. Tyrosine kinase signaling in cancer metabolism: PKM2 paradox in the Warburg effect. Front Cell Dev Biol. 2018;6:79.

52. Tech K, Tikunov AP, Farooq H, Morrissy AS, Meidinger J, Fish T, et al. Pyruvate kinase inhibitors proliferation during postnatal cerebellar neurogenesis and suppresses medulloblastoma formation. Cancer Res. 2017;77:3217–30.

53. Dayton TL, Goecheva V, Miller KM, Israelson WJ, Bhuktar A, Clish CB, et al. Germline loss of PKM2 promotes metabolic distress and hepatocellular carcinoma. Genes Dev. 2016;30:1020–33.

54. Wang YH, Israelson WJ, Lee D, Yu VWC, Jeanson NT, Clish CB, et al. Cell-state-specific metabolic dependency in hematopoiesis and leukemogenesis. Cell. 2014;158:1309–23.

55. Dayton TL, Goecheva V, Miller KM, Bhuktar A, Lewis CA, Bronson RT, et al. Isoform-specific deletion of PKM2 constrains tumor initiation in a mouse model of soft tissue sarcoma. Cancer Metab. 2018;6:6.

56. Ghesquière B, Wong BW, Kuchnio A, Carmeliet P. Metabolism of stromal and immune cells in health and disease. Nature. 2014;511:167–76.

57. O’Neill LA, Hardie DG. Metabolism of inflammation limited by AMPK and pseudo-starvation. Nature. 2013;493:346–55.

58. O’Neill LA, Pearce EJ. Immunometabolism governs dendritic cell and macrophage function. J Exp Med. 2016;213:15–23.

59. Wang R, Green DR. Metabolic checkpoints in activated T cells. Nat Immunol. 2012;13:907–15.

60. Chang CH, Curtis JD, Maggi LB Jr, Faubert B, Villarino AV, O’Sullivan D, et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell. 2013;153:1239–51.

61. Biswas SK, Mantovani A. Orchestration of metabolism by macrophages. Cell Metab. 2012;15:432–7.

62. Goyal MS, Hawrylycz M, Miller JA, Snyder AZ, Raichle ME. Aerobic glycolysis in the human brain is associated with development and neotenic gene expression. Cell Metab. 2014;19:49–57.

63. Galluzzi L, Kepp O, Vander Heiden MG, Kroemer G. Metabolic targets for cancer therapy. Nat Rev Drug Discov. 2013;12:829–46.

64. Vander Heiden MG, DeBerardinis RJ. Understanding the intersections between metabolism and cancer biology. Cell. 2017;168:657–69.

65. Martinez-Outschoorn UE, Peiris-Pagés M, Pestell RG, Sotgia F, Lisanti MP. Cancer metabolism: a therapeutic perspective. Nat Rev Clin Oncol. 2017;14:11–31.

66. Zheng X, Boyer L, Jin M, Mertens J, Kim Y, Ma L, et al. Metabolic reprogramming during neuronal differentiation from aerobic glycolysis to neuronal oxidative phosphorylation. eLife. 2016;5:e13374. pii

67. Varum S, Rodrigues AS, Moura MB, Moricovici O, Easley CA 4th, Ramalho-Santos J, et al. Energy metabolism in human pluripotent stem cells and their differentiated counterparts. PLoS ONE. 2011;6:e20914.

68. Kondoh H, Lleonart ME, Nakashima Y, Yokode M, Tanaka M, Bernard D, et al. A high glycolytic flux supports the proliferative potential of murine embryonic stem cells. Antioxid Redox Signal. 2007;9:293–9.

69. Agathocleous M, Love NK, Randlett O, Harris JJ, Liu J, Murray AJ, et al. Metabolic differentiation in the embryonic retina. Nat Cell Biol. 2012;14:859–64.

70. Chung S, Arrell DK, Faustino RS, Terzic A, Dzeja PP. Glycolytic network restructuring integral to the energetics of embryonic stem cell cardiac differentiation. J Mol Cell Cardiol. 2010;48:725–34.

71. Fritz HL, SmoaK IW, Branch S. Hexokinase I expression and activity in embryonic mouse heart during early and late organogenesis. Histochem Cell Biol. 1999;112:359–64.

72. Nome JR, Quintanilla RA, Hoffman DL, de Mesy Bentley KL, Molkentin JD, Sheu SS, et al. The permeability transition pore controls cardiac mitochondrial maturation and myocyte differentiation. Dev Cell. 2011;21:469–78.

73. Martin OJ, Lai L, Soundararandian MM, Leone TC, Zorzano A, Keller MP, et al. A role for peroxisome proliferator-activated receptor γ coactivator-1 in the control of mitochondrial dynamics during postnatal cardiac growth. Circ Res. 2014;114:626–36.
48. Chang CH, Pearce EL. Emerging concepts of T cell metabolism
49. Shapouri-Moghaddam A, Mohammadian S, Vazini H, Taghadosi
50. Krawczyk CM, Holowka T, Sun J, Blagih J, Amiel E, DeBerardinis RJ, et al. Toll-like receptor-induced changes in glycolytic metabolism regulate dendritic cell activation. Blood. 2010;115:4742–9.
51. Everts B, Amiel E, van der Windt GJ, Freitas TC, Chott R, Folmes CD, Martinez-Fernandez A, Faustino RS, Yamada S, Zhou W, Choi M, Margineantu D, Margaretha L, Hesson J, Tannahill GM, Curtis AM, Adamik J, Palsson-McDermott EM, Semba H, Takeda N, Isagawa T, Sugiura Y, Honda K, Wake M, Lee SH, Hu LL, Gonzalez-Navajas J, Sato GS, Chen C, Brick J, et al. ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nat Cell Biol. 2012;14:1295–304.
52. Caunt CJ, Sale MJ, Smith PD, Cook SJ. MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road. Nat Rev Cancer. 2015;15:577–92.
53. Parmentier TJ, Kleinschmidt M, Kinross KM, Bond ST, Li J, Kaadge MR, et al. Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discov. 2014;4:423–33.
54. Shim H, Dolce C, Lewis BC, Wu CS, Dang G, Jungmann RA, et al. c-Myc transactivation of LDHA: implications for tumor metabolism and growth. Proc Natl Acad Sci USA. 2010;107:9658–6563.
55. Dang CV, Kim JW, Gao P, Yustein J. The interplay between MYC and HIF in cancer. Nat Rev Cancer. 2008;8:51–56.
56. Edmunds LR, Sharma L, Kang A, Lu J, Vockley J, Basu S, et al. c-Myc programs fatty acid metabolism and dictates acetyl-CoA abundance and fate. J Biol Chem. 2014;289:23582–92.
57. Stine ZE, Walton ZE, Altman BJ, Hsieh AL, Dang CV, MYC, metabolism, and cancer. Cancer Discov. 2015;5:1024–39.
58. Goetzman ES, Prochownik EV. The role of Myc in coordinating glycolysis, oxidative phosphorylation, glutaminolysis, and fatty acid metabolism in normal and neoplastic tissues. Front Endocrinol. 2018;9:129.
59. David CJ, Chen M, Assanah M, Canoll P, Manley JL. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature. 2010;463:364–8.
60. Hall A, Meyle KD, Lange MK, Klima M, Sandershoff M, Dalgic S, Winter S, et al. Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the (V600E) BRAF oncogene. Oncotarget. 2013;4:584–99.
61. Haq R, Shaog J, Andreeu-Perez P, Yokoyama S, Edelman H, Rowe GC, et al. Oncogenic BRAF regulates oxidative metabolism in normal and neoplastic tissues. Front Endocrinol. 2018;9:129.
62. Board RE, Ellison G, Orr MC, Kemsley KR, McWalter G, et al. Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study. Br J Cancer. 2009;101:1724–30.
63. Dankner M, Rose AAN, Rajkumar S, Siegel PM, Watson IR. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. Oncogene. 2018. https://doi.org/10.1038/s41388-018-0171-x.
64. Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H, et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science. 2009;325:1555–9.
65. Lee MH, Lee SE, Kim DW, Ryu MJ, Kim SJ, Kim SJ, et al. Mitochondrial localization and regulation of BRAFV600E in
thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E. J Clin Endocrinol Metab. 2011;96:E19–30.

112. Michailakis ED, Webster L, Mackey JR. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer. 2008;99:989–94.

113. Minoiti MF, Arunan V, Ekyen TR, Marais R, Workman P, Leach MO, et al. MEK1/2 inhibition decreases lactate in BRAF-driven human cancer cells. Cancer Res. 2013;73:4039–49.

114. Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, Fletcher-Sanankome E, et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell. 2012;149:656–70.

115. Li X, Jiang Y, Meisenhelder J, Yang W, Hawke DH, Zheng Y, et al. Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. Mol Cell Biol. 2005;25:6225–33.

116. Grassian AR, Metallo CM, Coloff JL, Stephanopoulos G, Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, et al. In vitro propagation and transcriptional dynamics are temporally controlled by c-Myc. PLoS ONE. 2012;7:e37699.

117. Michelakis ED, Webster L, Mackey JR. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer. 2008;99:989–94.

118. Wu N, Zheng B, Shaywitz A, Dagon Y, Tower C, Bellinger G, et al. AMPK-dependent degradation of TXNIP upon energy stress leads to enhanced glucose uptake via GLUT1. Mol Cell. 2013;49:1167–75.

119. Hardie DG. Molecular pathways: is AMPK a friend or a foe in cancer? Mol Cancer Res. 2015;13:237–33.

120. Hardie DG. AMPK in cancer: a potential therapeutic target. Mol Cancer. 2016;15:69.

121. Chen N, Nomura M, She QB, Bode AM, Wang L, et al. Suppression of skin tumorigenesis in c-Jun NH2-terminal kinase-2-deficient mice. Cancer Res. 2001;61:3908–12.

122. Barbarulo A, Iansante V, Chaidos A, Naresh K, Rahemtulla A, Frangosso G, et al. Poly(ADP-ribose) polymerase family member 14 (PARP14) is a novel effector of the JNK2-dependent pro-survival signal in multiple myeloma. Oncogene. 2013;32:4231–42.

123. Través PG, de Atauri P, Marín S, Pimentel-Santillana M, Rodríguez-Prados JC, Marín de Mas I, et al. Relevance of the MEK/ERK signaling pathway in the metabolism of activated macrophages: a metabolomic approach. J Immunol. 2012;188:1402–10.

124. Bubici C, Papa S. JNK signalling in cancer: in need of new, smarter therapeutic targets. Br J Pharmacol. 2014;171:24–37.

125. Anbalagan M, Sabapathy K. JNK1 and JNK2 play redundant roles in c-Jun NH2-terminal kinase signalling and cell stress response. Mol Metab. 2016;6:174–84.

126. Graves JA, Wang Y, Sims-Lucas S, Cherok E, Rothermund K, Branca MF, et al. Mitochondrial structure, function and dynamics are temporally controlled by c-Myc. PLoS ONE. 2012;7:e37699.

127. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371:1877–88.

128. Hardeman KN, Peng C, Paudel BB, Meyer CT, Luong T, Tyson DR, et al. Dependence on glycolysis sensitizes BRAF-mutated melanomas for increased response to targeted BRAF inhibition. Sci Rep. 2017;7:42604.

129. Solinas G, Becattini B. JNK at the crossroad of obesity, insulin resistance, and cell stress response. Mol Metab. 2016;5:174–84.

130. Papa S, Bubici C. Linking apoptosis to cancer metabolism: another missing piece of the puzzle. J Nucl Med. 2016;5:1103–9.

131. Khamari R, Trinh A, Gabert PE, Corazao-Rozas P, Riveros-Cruz S, Balayssac S, et al. Glucose metabolism and NRF2 coordinate the antioxidant response in melanoma resistant to MAPK inhibitors. Cell Death Dis. 2018;9:325.

132. Zhao Y, Adjei AA. The clinical development of MEK inhibitors. Nat Rev Clin Oncol. 2014;11:385–400.

133. Dixit D, Ghildiyal R, Anto NP, Sen E. Chaetocin-induced ROS-signaling of human mammary stem/progenitor cells. Genes Dev. 2006;20:633–47.
dependent inhibition of glucose metabolism. Cell Death Dis. 2014;5:e1212.

148. Nemoto S, Takeda K, Yu ZX, Ferrans VJ, Finkel T. Role for mitochondrial oxidants as regulators of cellular metabolism. Mol Cell Biol. 2000;20:7311–8.

149. Shanware NP, Bray K, Eng CH, Wang F, Follettie M, Myers J, et al. Glutamine deprivation stimulates mTOR-JNK-dependent chemokine secretion. Nat Commun. 2014;5:4900.

150. Yang R, Wilcox DM, Haasch DL, Jung PM, Nguyen PT, Voorbach MJ, et al. Liver-specific knockdown of JNK1 up-regulates proliferator-activated receptor gamma coactivator 1 beta and increases plasma triglyceride despite reduced glucose and insulin levels in diet-induced obese mice. J Biol Chem. 2007;282:22765–74.

151. Vernia S, Cavanagh-Kyros J, Garcia-Haro L, Sabio G, Barrett T, Jung DY, et al. The PPARα-FGF21 hormone axis contributes to metabolic regulation by the hepatic JNK signaling pathway. Cell Metab. 2014;20:512–25.

152. Deng H, Yu F, Chen J, Zhao Y, Xiang J, Lin A. Phosphorylation of Bad at Thr-201 by JNK1 promotes glycolysis through activation of phosphofructokinase-1. J Biol Chem. 2008;283:20754–60.

153. Zhou Q, Lam PY, Han D, Cadenas E. c-Jun N-terminal kinase regulates mitochondrial bioenergetics by modulating pyruvate dehydrogenase activity in primary cortical neurons. J Neurochem. 2008;104:325–35.

154. Ke H, Harris R, Coloff JL, Jin JY, Leshin B, Miliani de Marval P, et al. The c-Jun NH2-terminal kinase 2 plays a dominant role in human epidermal neoplasia. Cancer Res. 2010;70:3080–8.

155. Papa S, Bubici C, Zazzeroni F, Pham CG, Kuntzen C, Knabb JR, et al. The NF-kappaB-mediated control of the JNK cascade in the antagonism of programmed cell death in health and disease. Cell Death Differ. 2006;13:712–29.